Elite HIV controllers: myth or reality? (Abstract) Print E-mail
Monday, 01 October 2007 00:00
Despite the varying disease progression rates, the majority of HIV-infected individuals eventually progress to AIDS. There is a subset of HIV-positive individuals, who maintain high CD4+ and CD8+ T-cell counts, remain therapy naive and persistently infected with HIV-1 for more than 15 to 20 years. In light of current observations, this subset can be divided into two groups. One shows low detectable plasma viremia (< 5000 HIV-RNA copies/ml), termed long-term nonprogressors. A second group shows plasma HIV-RNA values persistently below 50 copies/ml throughout the course of infection, and termed "elite" or "natural controllers". The features common between both groups are the presence of high CD4+ and CD8+ T-cell counts, strong immune responses, and low but variable cellular proviral DNA load. The group of HIV-positive long-term nonprogressor individuals comprises about 1% of the total HIV population in the world, whereas the "elite" controllers may be much less. Why do some people deteriorate faster, while others remain normal both symptomatically and immunologically for decades?
There is a renewed interest in HIV-positive individuals who have survived since the period close to the earlier part of the HIV pandemic in the 1980s and have remained drug-naive. As very little is known about "elite" controllers, the findings discussed here are largely based on previously known and newly emerging aspects of HIV pathogenesis in the context of the long-term nonprogressor group. It is believed that data emerging on long-term nonprogressors will allow us to make scientific inferences to further our research on "elite" controllers. Aspects dealing with cellular, humoral, innate, and adaptive immunity, which are relevant to nonprogressive HIV disease, are beyond the scope of this review.

Retroviral Genetics Division, Westmead Millennium Institute, Westmead Hospital, Westmead NSW, Sydney, Australia. This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Link: PubMed
Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Monday, 05 April 2010 14:23 )

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page: zephyrfoundation.org
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Controllers in Study

 Donation Thermometer
 Donation Thermometer
 Donation Thermometer

Our Goal:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other